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Summary 
SH-PTP2, the vertebrate homolog of Drosophila cork. 
screw, associates with several activated growth factor 
receptors, but its biological function is unknown. We 
assayed the effects of injection of wild-type and mu- 
tant SH-PTP2 RNAs on Xenopus embryogenesis. An 
internal phosphatase domain deletion (AP) acts as a 
dominant negative mutant, causing severe posterior 
truncations. This phenotype is rescued by SH-PTP2, 
but not by the closely related SH-PTP1. In ectodermal 
explants, AP blocks fibroblast growth factor (FGF)- 
and activin-mediated induction of mesoderm and FGF- 
induced mitogen-activated protein (MAP) kinase acti- 
vation. Our results indicate that SH-PTP2 is required 
for early vertebrate development, acting as a positive 
component in FGF signaling downstream of the FGF 
receptor and upstream of MAP kinase. 
Introduction 
Several growth factors and their cognate receptor protein- 
tyrosine kinases (RPTKs) control developmental path- 
ways. let-23 is essential for Caenorhabditis elegans vulval 
development (Aroian et al., 1990). Drosophila sevenless 
determines photoreceptor cell fate (Hafen et al., 1987), 
whereas torso directs formation of anterior and posterior 
structures (Sprenger et al., 1989; Casanova and Struhl, 
1989). Murine hematopoiesis, melanogenesis, and ga- 
metogenesis require interaction between the steel gene 
product and its receptor c-Kit, encoded at the W locus 
(Pawson and Bernstein, 1990). 
A paradigm has emerged for RPTK signaling. Upon li- 
gand binding, RPTKs dimerize, activate, and transphos- 
phorylate on multiple tyrosines (Schlessinger and UIIrich, 
1992). Activated receptors transmit signals by recruiting 
secondary signaling molecules containing Src-homology 
2 (SH2) domains, conserved stretches of about 100 amino 
acids that bind with high affinity to specific phosphotyro- 
sine residues. Some secondary signaling proteins also 
have Src-homology 3 (SH3) domains, which bind to pro- 
line-rich peptide targets. SH2- and SH3-mediated interac- 
tions relocate enzymes such as phosphoinositide-3- 
kinase (PI3-kinase), phospholipase Cy, and Ras-GAP to 
their substrates, and/or increase their enzymatic activity 
(Koch et al., 1991 ; Schlessinger, 1994). These events cul- 
minate in activation of pathways uch as the Ras/Raf/mito- 
gen-activated protein kinase (MAPK) cascade (Marshall, 
1994). 
Several RPTK targets are required for normal develop- 
ment. sem-5 (Clark et al., 1992), the homolog of Drosophila 
downstream of receptor kinases (drk) (Simon et al., 1993; 
Olivier et al., 1993), mammalian GRB2 (Lowenstein et al., 
1992), and let-60 (Han et al., 1990), a c-ras homolog, are 
required downstream of let-23. Likewise, Son ofsevenless 
(Sos), which encodes a Ras GTP/GDP exchange protein 
(Simon et al., 1991), Rasl (Simon et al., 1991), and rolled, 
a MAPK homolog (Brunner et al., 1994), are essential for 
sevenless signaling. 
Much less is known about protein-tyrosine phosphatase 
(PTP) function (Walton and Dixon, 1993). The cloning of 
SH2-containing PTPs (SH-PTPs) suggested that these 
molecules might participate in the regulation of RPTK sig- 
naling (Neel, 1993). Two vertebrate SH-PTPs sharing a 
similar protein structure (see Figure 1) consisting of two 
N-terminal SH2 domains, a PTP domain, and a C-terminus 
with phosphorylation sites have been described. SH-PTP1 
(Plutzky et al., 1992), also termed PTP1C (Shen et al., 
1991), HCP (Yi et al., 1992), or SHP (Matthews et al., 
1992), is expressed mainly in hematopoietic ells. Its key 
role in hematopoiesis is illustrated by the finding that SH- 
PTP1 mutations cause the motheaten mouse (Tsui et al., 
1993; Shultz et al., 1993). 
SH-PTP2 (Freeman et al., 1992), also termed Syp (Feng 
et al., 1993), PTP1D (Vogel et al., 1993), and PTP2C (Ah- 
mad et al., 1993), is expressed ubiquitously. It is the homo- 
log of Drosophila corkscrew (csw) (Perkins et al., 1992), 
which is required maternally as a positive signal trans- 
ducer downstream of torso. Csw contains an insert of 150 
amino acids within its PTP domain and lacks one of the two 
C-terminal tyrosine phosphorylation sites present within 
SH-PTP2. The biological significance of these differences 
has not been determined. Moreover, no role for SH-PTP2 
in vertebrate development has been established. 
Progress has been made in defining SH-PTP2 signaling 
pathways. SH-PTP2 associates with several activated 
RPTKs, including the platelet-derived growth factor recep- 
tor (PDGFR) and epidermal growth factor receptor (EGFR) 
(Feng et al., 1993; Vogel et al., 1993; Lechleider et al., 
1993b) as well as with the insulin receptor substrate IRS-1 
(Kuhne et al., 1993). Specific binding sequences for its 
SH2 domains have been defined in the PDGFR (Lech- 
leider et al., 1993a; Kazlauskas et al., 1993; Feng et al., 
1994) and IRS-1 (Sun et al., 1993; Case et al., 1994), and 
a consensus binding sequence has been elucidated 
(Songyang et al., 1993; Case et al., 1994). SH-PTP2 be- 
comes tyrosine phosphorylated in response to PDGF and 
EGF (Feng et al., 1993; Vogel et al., 1993; Lechleider et 
al., 1993b). The sequences of the induced phosphoryla- 
tion sites within the SH-PTP2 C-terminus (Bennett et al., 
1994) suggested a mechanism for positive signaling in 
which tyrosine-phosphorylated SH-PTP2 recruits GRB2/ 
Sos to the activated PDGFR, thereby activating Ras (Li 
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Figure 1. Molecular Cloning and Expression of XSH-PTP2 
(A) Deduced amino acid sequence for XSH-PTP2. SH2 domains are 
indicated by solid lines and the PTP domain by italics. 
(13) Comparison of the structure of XSH-PTP2 to HSH-PTP2 and csw, 
indicating a high degree of conservation. Percent identities are indi- 
cated. XSH-PTP2 and HSH-PTP2 lack an insert in the phosphatase 
domain. Two potential tyrosine phosphorylation sites are conserved 
from XSH-PTP2 to HSH-PTP2; one is also found in csw. All three 
homologs retain a proline-rich sequence within their C-termini. 
(C) Northern blot of SH-PTP2 expression in early Xenopus develop- 
ment. Numbers across the top indicate developmental stage. XSH- 
PTP2 is expressed as an approximately 3 kb transcript, present in 
oocytes (M) and fertilized eggs ( tage 1) through tadpole (stage 38). 
The blot was reprobed with Xenopus fibronectin to control for RNA 
integrity. Fibronectin RNA levels increase in the later stages of normal 
embryogenesis. The apparent decrease in XSH-PTP2 RNA expres- 
sion in mid-embryonic stages is not observed reproducibly. 
(D) Maternal expression of XSH-PTP2 protein. Recombinant HSH- 
PTP2 (50 and 100 ng) in total cell lysates from baculovirus-infected 
Sf9 cells (lanes A and B, respectively) and soluble protein from the 
equivalent of one-half (1/2) or one oocyte (lanes C and D, respectively) 
were detected by immunoblotting with anti-PTPID/SH-PTP2 mono- 
clonal antibody. 
et al., 1994; Bennett et al., 1994). The role of the PTP 
domain in signaling has remained unclear. In addition, it 
is unclear how SH-PTP2 might participate in insulin signal- 
ing, since insulin does not stimulate SH-PTP2 tyrosine 
phosphorylation (Kuhne et al., 1993). 
In view of the function of csw, we asked whether SH- 
PTP2 is required for vertebrate development. The classic 
experiments of Nieuwkoop (1969) in Xenopus suggested 
that mesoderm arises as a result of inductive interactions 
between vegetal pole and animal pole cells. Much work 
has implicated peptide growth factors and their receptors 
in this process (Klein and Melton, 1994). In the absence 
of growth factors, animal pole (ectodermal) explants of 
stage 8 Xenopus embryos (animal caps) undergo epider- 
mal differentiation. Addition of members of the fibroblast 
growth factor (FGF) (e.g., bFGF) or transforming rowth 
factor 13 (TGFI~) families (e.g., activin) to such explants can 
induce mesoderm. Both factors and their receptors are 
present in the early embryo (Klein and Melton, 1994). A 
dominant negative mutant of a Xenopus FGF receptor 
blocks the effects of FGF on ectodermal explants and in- 
terferes with normal trunk and tail development (Amaya 
et al., 1991, 1993), whereas expression of a truncated 
activin receptor prevents formation of most, if not all meso- 
derm (Hemmati-Brivanlou and Melton, 1992). Such stud- 
ies implicate signaling by FGF and TGFI3 family members 
in early development in vivo. 
To test the involvement of SH-PTP2 in mesoderm induc- 
tion, we cloned Xenopus SH-PTP2, found that it is ex- 
pressed maternally, and assayed the effects of injection 
of wild-type and various mutant SH-PTP2 RNAs on early 
development. An internal PTP domain deletion (AP) acted 
as a dominant negative mutant of SH-PTP2, resulting in 
severe posterior truncations. In animal caps, AP blocks 
FGF- and activin-mediated mesoderm induction. Further- 
more, we show that SH-PTP2 acts upstream of MAPK in 
FGF receptor (FGFR) signaling. 
Results 
Cloning and Characterization of Xenopus SH-PTP2 
If SH-PTP2 is involved in mesoderm induction, it must be 
supplied maternally, because zygotic transcription does 
not begin until after the mid-blastula transition (Newport 
and Kirschner, 1982b). We molecularly cloned the Xeno- 
pus homolog of SH-PTP2 (XSH-PTP2) by sequential 
screening of cDNA libraries (see Experimental Proce- 
dures). We also cloned Xenopus SH-PTP1 (XSH-PTP1); 
the sequence of this clone will be reported elsewhere. Like 
human SH-PTP2 (HSH-PTP2), XSH-PTP2 contains two 
SH2 domains N-terminal to a consensus PTP domain as 
well as a C-terminal hydrophilic tail (Figures 1A and 1 B). 
HSH-PTP2 and XSH-PTP2 are 100%, 96%, 93%, and 
88% identical through the N-terminal SH2 domain, C-ter- 
minal SH2 domain, PTP dcmain, and C-terminal tail, re- 
spectively; overall identity is 94%. XSH-PTP2 lacks an 
insert in its PTP domain. Both tyrosine phosphorylation 
sites present in the C-terminus of HSH-PTP2 are con- 
served in XSH-PTP2; only the more N-terminal of these 
sites is found in csw. The SH-PTP2 homologs all retain a 
proline-rich sequence comprising a potential SH3 binding 
site within their C-termini. These conserved structural 
components are likely to be important functionally. North- 
ern analysis revealed that XSH-PTP2 RNA is present at 
similar levels maternally and zygotically (Figure 1C). SH- 
PTP2 protein was easily detected by immunoblot analysis 
in oocytes (Figure 1 D) and early embryos (see Figure 4D; 
data not shown), consistent with the possibility that XSH- 
PTP2 is involved in early embryogenesis. 
A Dominant Negative SH-PTP2 Mutant Alters 
Xenopus Embryonic Development 
To probe the role of endogenous XSH-PTP2 in Xenopus 
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Figure 2. Microinjection Constructs 
Shown are schematics of human and Xenopus SH-PTP1 and SH-PTP2 
including the N- (SH2-N) and C-terminal (SH2-C) SH2 domains, the 
PTP domain, and the C-terminal tail. HSH-PTP2 mutant constructs 
are also depicted including the PTP-inactive construct (AP), containing 
a 31 amino acid deletion in the critical catalytic ore, and three 
C-terminal tyrosine to phenylalanine point mutants, consisting of two 
single point mutations (Y542F, Y580F) and the double point mutant 
(Y542,580F). 
embryos and to test the fun ction of various SH-PTP2 struc- 
tural domains (specifically, the PTP domain and the C-ter- 
minal region), several altered HSH-PTP2 cDNAs were 
constructed (Figure 2). We reasoned that SH-PTP2 mole- 
cules containing a PTP domain deletion (AP) and/or point 
mutations of its C-terminal tyrosines might act as dominant 
negative mutants. A PTP domain deletion was used, rather 
than a C-+S mutation of the essential catalytic cysteine 
(Guan and Dixon, 1991), because C-+S mutants can se- 
quester substrates (Bliska et al., 1992). Thus, the effects 
of a C~S mutant might be more difficult o interpret. The 
mutations were introduced into HSH-PTP2 so that the in- 
jected product and endogenous XSH-PTP2 could be dis- 
tinguished. Given the identity of the N-terminal SH2 do- 
main and the strong conservation of the rest of the 
molecule, we were confident that HSH-PTP2 constructs 
would retain function within the Xenopus embryo. 
RNA synthesized from wild-type and mutant HSH-PTP2 
plasmid constructs was injected into the dorsal marginal 
zone of 4- to 8-cell embryos. Embryos injected with water, 
full-length XSH-PTP2 (Figures 3A and 3C) or HSH-PTP2, 
or C-terminal Y--*F mutants (data not shown) developed 
normally (Figures 3A and 3C; Table 1). Embryos injected 
with AP RNA developed through the blastula stages and 
entered gastrulation ormally, forming blastopore lips on 
their dorsal sides. However, they failed to complete gastru- 
lation. Their blastopores remained open (Figure 3B), and 
as a result, the neural tube did not close and their tails 
were truncated in the early tadpole (stage 44) (compare 
Figures 3C and 3D). Histological analysis confirmed that 
anterior development of AP embryos was normal (data not 
shown). Transverse sections revealed that mesodermal 
tissues were present and organized. However, at the mid- 
trunk level, the notochord and neural tube were split. The 
somites were not duplicated and were generally found lat- 
eral to the notochord(s) (Figures 3E and 3F). This pheno- 
type is similar to those produced by expression of domi- 
nant negative FGFR (Amaya et al., 1991) or dominant 
negative Raf (MacNicol et al., 1993). The occurrence and 
severity of the phenotype were dependent on the dose of 
AP (Figure 3G). All subsequent experiments were per- 
formed at 5 ng/embryo. 
We compared the expression of early mesodermal 
markers in embryos injected in the marginal zones of all 
four blastomeres at the 4-cell stage. In Xenopus, Brachy- 
ury (Xbra), Xwnt8, and goosecoid (gsc) are normally ex- 
pressed throughout gastrulation (stage 12) (Dawid, 1991). 
In agreement with previous work (Amaya et al., 1991, 
1993), injection of dominant negative FGFR RNA blocks 
Xbra expression. AP also inhibits Xbra expression, 
whereas Xwnt8 and gsc levels are similar to controls (Fig- 
ure 3H). 
Since immunoblotting revealed that RNAs from the C-ter- 
minal point mutant constructs were translated efficiently 
in injected embryos (data not shown), our results argue 
against these mutants acting as dominant negatives in 
Xenopus development (see below and Discussion). The 
similarity of the phenotype induced by AP injection to that 
caused by dominant negative FGFR RNA suggested that 
XSH-PTP2 might be a key component in FGF signaling. 
Therefore, we set out to determine the specificity of the 
AP effect. 
Rescue of AP-Induced Defects by Expression 
of Wild-Type XSH-PTP2 
We reasoned that AP is a dominant negative mutant hat 
acts by binding, via its SH2 domains, to upstream regula- 
Table 1. Injection of AP and Wild-Type SH-PTP2 RNA 
Phenotype of Embryos at Stage 22 
Number of Number of % Tail % Partial 
RNA Injected Experiments Embryos % Normal Truncat ion  Truncation % Other 
AP 7 158 28 53 16 • 3 
XSH-PTP2 4 84 94 0 2 4 
AP:XSH-PTP2 4 112 73 6 9 12 
XSH-PTP1 2 45 100 0 0 0 
AP:XSH-PTP1 2 53 23 56 4 17 
H20 5 107 95 2 0 3 
Embryos were injected with 2-5 ng of RNA at the 4- to 8-cell stage and scored for defects at stage 22. Embryos were coinjected at a 1:0.5 ratio 
(5 ng AP to 2.5 ng SH-PTP2 or SH-PTP1). % Other includes embryos with bifurcated tails or nonspecific abnormalities. 
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Figure 3. AP RNA Injection Results in Embryos with Severe Tail Trun- 
cations 
Four- to eight-cell embryos were injected in the dorsal marginal zone 
with wild-type XSH-PTP2 or AP RNA and allowed to develop• 
(A-D) Morphology of injected embryos. Embryos were scored for de- 
velopmental bnormalities at stage 18 (A and B) and stage 44 (C and 
D): embryos injected with XSH-PTP2 RNA (A and C); embryos injected 
with AP RNA (B and D). The phenotype of AP-injected embryos at 
stage 18 reflects failure of blastopore closure at the end of gastrulation. 
At stage 44, the extreme tail truncation of AP-injected embryos is 
evident• 
(E and F) Histological analysis. A transverse section at the back of 
the head of a normal, XSH-PTP2 RNA-injected tadpole is shown i
(E). Brain (b), somites ( ), and notochord (nc) are indicated. The scale 
bar in (E) represents 100 I~m, For comparison, in a more posterior 
section, a AP RNA-injected embryo is hown (F). Split notochord and 
neural tube (nt) are evident; somites are notduplicated• 
(G) Dose response of AP RNA injection. Increasing amounts of AP 
RNA were injected into 4- to 8-cell embryos, which were allowed to 
develop to stage 18 and scored for tail truncation. 
(H) Inhibition of Xbra expression by injection of AP RNA. Northern 
blot of RNA from stage 11 embryos, injected in the marginal zone of 
all four blastomeres at the 4-cell stage with water control (C),SH-PTP2 
PTP domain mutant RNA (AP), wild-type XSH-PTP2 RNA (WT), domi- 
nant negative FGFR RNA (FRD), or wild-type FGFR RNA (FR), and 
tors of SH-PTP2. Lacking an active PTP domain, AP fails 
to dephosphorylate a key su bstrate(s). If the AP phenotype 
were due to a specific dominant negative effect, AP- 
injected embryos should be rescued by coinjection of 
full-length SH-PTP2. Injection of AP RNA into 158 Xeno- 
pus embryos resulted in 53% grossly abnormal embryos. 
An additional 16% displayed a less extreme condition 
wherein tail truncation was evident but the backs of the 
embryos fused (Table 1). Both XSH-PTP2 (Figure 4C; Ta- 
ble 1) and HSH-PTP2 (data not shown) efficiently rescued 
the AP phenotype. Of 112 embryos coinjected with a 1:0.5 
ratio of AP to XSH-PTP2 RNA, almost all (73%) developed 
completely normally; only a small fraction (6%) showed 
no evidence of rescue (Figure 4C; Table 1). Thus, increas- 
ing the amount of wild-type SH-PTP2 can overcome the 
developmental defects caused by AP. The AP phenotype 
was also rescued by SH-PTP2 RNA containing Y--*F muta- 
tions in both C-terminal tyrosine phosphorylation sites 
(data not shown). These data argue against the SH2 do- 
mains of AP sequestering upstream phosphotyrosine pro- 
teins indiscriminately. Since AP and HSH-PTP2 presum- 
ably differ only in that the former lacks PTP activity, PTP 
activity likely is required for SH-PTP2 signaling in early 
Xenopus development. 
As a further test of specificity, we asked whether AP 
was also rescued by SH-PTP1. Injection of SH-PTP1 RNA 
into embryos over a wide range of concentrations had no 
effect upon early development (Table 1; data not shown). 
Moreover, coinjection of AP with XSH-PTP1 (or HSH- 
PTP1) did not rescue (Figure 4B). Failure to rescue was 
not due to absence of SH-PTP1 expression, as shown 
by immunoblotting. Our anti-SH-PTP1 antibodies do not 
cross-react with XSH-PTP1; hence, we could not rigor- 
ously show that XSH-PTP1 was expressed in coinjected 
embryos. However, we were able to detect full-length 
HSH-PTP1 protein easily (Figure 4D). Quantitative immu- 
noblots using baculovirus-expressed HSH-PTP1 and 
HSH-PTP2 indicated that the anti-SH-PTP1 and anti-SH- 
PTP2 antibodies are comparably sensitive (data not 
shown). Whereas HSH-PTP2 efficiently rescues the AP 
phenotype (Figure 4C; Table 1), comparable amounts of 
HSH-PTP1 protein (Figure 4D) were completely ineffective 
(Figure 4B; Table 1). The anti-SH-PTP2 antibody is di- 
rected against the N-terminal SH2 domain (see Experi- 
mental Procedures). This domain is precisely conserved 
in Xenopus and human (see Figure 1), so comparison of 
the intensity of the AP and endogenous XSH-PTP2 bands 
indicates their relative levels. Approximately a 5-fold ex- 
cess of AP induced tail truncation. These data argue fur- 
ther against binding of AP SH2 domains to inappropriate 
targets and imply that the AP phenotype is due to specific 
interference with SH-PTP2. 
probed with the indicated early mesodermal markers. Injection of ei- 
ther AP or FRD inhibits Xbra expression. The same blot rehybridized 
with a fibronectin probe (FN) serves as a control for RNA loading and 
integrity. 
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Figure 4. AP-Injected Embryos Are Rescued By Coinjection of Wild- 
Type XSH-PTP2 
(A-C) Embryos were injected at the 4- to 8-cell stage with the indicated 
RNAs. (A) Embryos injected with wild-type XSH-PTP2. (B) Embryos 
coinjected with AP and wild-type XSH-PTP1 (5 ng AP:2.5 ng XSH- 
PTP1); all of the embryos shown display the mutant phenotype. (C) 
Coinjection of AP with wild-type XSH-PTP2 RNA (5 ng AP:2.5 ng XSH- 
PTP2) rescues almost all the mbryos; in the top left corner is an 
embryo that was not rescued. 
(D) Immunoblot analysis ofinjected embryos. Embryos coinjected with 
AP RNA and wild-type HSH-PTP1 RNA (5 ng AP:2.5 ng HSH-PTP1) 
were harvested at stage 11 for protein analysis. (Left panel) Anti- 
SH-PTP1 immunoblot: no HSH-PTP1 is detectable in the uninjected 
lane (1), but full-length HSH-PTP1 is found in the coinjected lane (2). 
This blot was reprobed with anti-PTP1D/SH-PTP2 monoclonal anti- 
body (right panel). AP protein is detected in the coinjected lane (2). 
Cross-reaction of this antibody with XSH-PTP2 (upper band seen in 
both lanes 1 and 2, right panel) acts as a control for protein loading 
and shows the relative levels of AP and endogenous XSH-PTP2. 
Figure 5. AP Injection Blocks FGF-Mediated Elongation of Animal 
Caps 
One- to two-cell embryos were injected with AP RNA, then allowed 
to develop to stage 8. Animal caps were treated for 3 hr with 100 
ng/ml bFGF or 5 ng/ml human recombinant activin A. (a) Untreated 
controls; (b) uninjected animal caps treated with bFGF; (c) animal caps 
from embryos injected with AP FIN& treated with bFGF; (d) animal 
caps from embryos injected with wild-type XSH-PTP2 RNA, treated 
with bFGF; (e) untreated controls; (f)uninjected animal caps treated 
with activin; (g) animal caps from embryos injected with AP RNA, 
treated with activin; (h) animal caps from embryos injected with wild- 
type XSH-PTP2 RNA, treated with activin. 
Effects of SH-PTP2 Inhibition on Growth Factor 
Stimulation of Animal Caps 
We also assayed the effect of AP on mesoderm induction 
in ectodermal explants (animal caps). Upon treatment with 
bFGF or activin, animal caps normally undergo extensive 
elongation. Injection of AP blocked FGF-induced animal 
cap elongation; XSH-PTP2 injection had no effect(Figures 
5C and 5D). Activin-induced elongation was also blocked 
by AP (Figure 5G). This may indicate that an intact FGF 
signaling pathway is required for activin action (LaBonne 
and Whitman, 1994; Cornell and Kimelman, 1994), rather 
than direct participation of SH-PTP2 in activin signaling 
(see Discussion). 
The morphological effects induced by AP were accom- 
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Figure 6. AP Inhibits Expression of Early and Late Mesodermal Mark- 
ers in Animal Caps 
(A) Inhibition of Xbra expression. One- to two-cell embryos were in- 
jected with AP or wild-type XSH-PTP2 RNA, then allowed to develop 
to stage 8. Animal caps were either left untreated (minus) or treated 
for 3 hr with 100 ng/ml bFGF (~olus F) or 5 ng/ml activin A (plus A),
and RNA was prepared at stage 11. The resulting Northern blot was 
probed with the early marker Xbra and fibronectin (FN). Expression 
of these markers in total embryos (TE) is also shown. Injection of Ap 
RNA inhibits Xbra expression, whereas injection of wild-type XSH- 
PTP2 (WT) has no effect. Xbra expression is not detected in ~P- 
injected embryos even upon longer exposure of the blot. 
(B) Inhibition of muscle actin expression. One- to two-cell embryos 
were injected with AP or wild-type XSH-PTP2 RNA, and animal caps, 
prepared at stage 8 as in (A), were either left untreated (minus) or 
treated for 3 hr with 100 ng/ml bFGF or 5 ng/ml activin A,as indicated. 
RNA prepared at stage 11was used for Northern analysis with an actin 
probe. In both the uninjected and XSH-PTP2 RNA-injected lanes, 
induction of muscle-specific a tin (arrow) is evident upon bFGF treat- 
ment. Ap injection blocks muscle actin induction. An analogous result 
is seen for activin-induced muscle actin expression. The actin probe 
cross-hybridizes with cytoplasmic actin (the two upper bands seen in 
both blots), which is not induced by either bFGF or activin A treatment, 
thus providing a control for RNA loading. 
panied by defects in marker expression (Figure 6). Elonga- 
tion is accompanied by induction of early markers, such 
as Xbra (Smith et al., 1991), and late markers, such as 
muscle-specific actin (Dworkin-Rastl et al., 1986). Xbra 
induction by FGF or activin was decreased in AP-injected 
embryos, compared with uninjected controls (Figure 6A). 
FGF- and activin-stimulated xpression of muscle-specific 
actin were also blocked in AP-injected animal caps; AP 
had no effect upon cytoplasmic actin expression, which 
serves as a loading control (Figure 6B). 
SH-PTP2 Acts Upstream of MAPK 
These data suggested that SH-PTP2 functions down- 
stream from the FGFR in mesoderm induction. As in many 
RPTK signaling pathways (Marshall, 1994), MAPK be- 
comes activated upon bFGF addition to animal caps (La- 
Bonne and Whitman, 1994; Graves et al., 1994; Hartley 
et al., 1994). SH-PTP2 could act upstream or downstream 
29.5-- 
Figure 7. Ap RNA Injection Blocks MAPK Activation by FGF 
One- to two-cell embryos were injected in the animal pole with Ap 
RNA and allowed to develop to stage 8. Animal caps were dissociated 
in calcium-free, magnesium-free, normal amphibian media (see Exper- 
imental Procedures), treated with 100 nglml bFGF for 5 min, and pel- 
leted and frozen for protein analysis. Total lysates from these cells 
were separated by SDS-PAGE and transferred to Immobilon. The 
blot was probed with anti-Xenopus MAPK rabbit polyclonal antibodies 
followed by anti-rabbit-horseradish peroxidase secondary antibodies 
and development by ECL. Duplicate experiments are shown. The de- 
crease in electrophoretic mobility denotes MAPK activation. MAPK 
activation is blocked in animal cap cells from AP-injected embryos. 
of (or parallel to) MAPK. If SH-PTP2 acts upstream, Ap 
should block MAPK activation by bFGF, whereas if it is 
downstream (or parallel), MAPK activation should occur. 
We injected one-to two-cell embryos with Ap and allowed 
development to stage 8, Animal caps were prepared and 
dissociated in order to maximize cell exposure to bFGF 
(LaBonne and Whitman, 1994). MAPK activation in Xeno- 
pus (Posada and Cooper, 1992) and other systems (Mar- 
shall, 1994) is due to phosphorylation on tyrosine and 
threonine residues and is marked by a mobility shift on 
SDS-polyacrylamide gels. MAPK from uninjected cells 
displayed the expected mobility shift in response to bFG F 
(Figure 7). However, in &P-injected cells, the lower mobil- 
ity form did not appear, indicating that FGF failed to acti- 
vate MAPK. 
Discussion 
We have cloned Xenopus SH-PTP2 and found that, like 
its Drosophila homolog csw (Perkins et al., 1992), XSH- 
PTP2 is expressed maternally. By examining the effects 
of a dominant negative mutant (Ap), we have shown that 
SH-PTP2 plays a critical role in vertebrate mbryogenesis. 
Expression of Ap in Xenopus embryos causes severe pos- 
terior truncations. In animal cap assays, Ap inhibits the 
response to both FGF and activin, as assayed morphologi- 
cally, histologically, and molecularly. Finally, we have 
shown that SH-PTP2 acts upstream of MAPK within the 
FGFR signaling pathway. Our data thus establish verte- 
brate SH-PTP2 as a positive signal transducer in vivo and 
demonstrate that i s PTP domain is essential for positive 
signaling. This work provides the first example of a PTP 
required for early events in vertebrate development, thus 
complementing earlier studies implicating peptide growth 
factors, RPTKs, and downstream components of RPTK 
signal transduction pathways (Klein and Melton, 1994). 
Several lines of evidence support our contention that 
AP is a specific dominant negative mutant. Although over- 
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expression of wild-type XSH-PTP2 or HSH-PTP2 alone 
has no effect, coinjection of either RNA efficiently rescues 
the AP phenotype. If the effects of ~P were due solely to 
expression of an excess of $H2 domains that gratuitously 
bind to multiple upstream phosphotyrosyl proteins, then 
coinjection of SH-PTP2 should potentiate the AP pheno- 
type, because more SH2 domains would be available. In- 
stead, our data are most consistent with competition be- 
tween the SH2 domains of wild-type XSH-PTP2 and AP 
for a limited number of upstream targets; the balance be- 
tween the two, and thus the ability of wild-type SH-PTP2 
to rescue, can be altered by changing their relative levels 
of expression. Rescue of AP did not occur by competition 
for translation of the coinjected RNAs, and specificity of 
rescue is further supported by quantitative immunoblot- 
ting, which shows that AP levels roughly 5-fold higher than 
XSH-PTP2 are capable of producing the abnormal pheno- 
type (Figure 4D; data not shown). Further evidence of 
specificity was provided by failure of the closely related 
XSH-PTP1 (or HSH-PTP1) to rescue, despite ample ex- 
pression in injected embryos (Figure 4D). Together with 
the finding that SH-PTP1 mutations cause severe defects 
in hematopoiesis (Tsui et al., 1993; Shultz et al., 1993) in 
the presence of normal levels of SH-PTP2 (unpublished 
data), our data provide compelling genetic evidence that 
the two vertebrate SH-PTPs, despite similar structures, 
have distinct biological functions. 
Injection of AP resulted in embryos with normal heads, 
but with dose-dependent severe tail truncations. Since 
gastrulation begins properly (normal involution of the dor- 
sal blastopore lip), and the heads of these embryos de- 
velop normally (Figures 3D and 4B), SH-PTP2 probably 
is not required for formation of head mesoderm. Involution 
of lateral and ventral marginal zone cells did not go to 
completion in AP-injected embryos, leaving the blastopore 
open. This results in embryos with unfused backs in their 
posterior regions. Although mesodermally derived struc- 
tures such as notochord and somites were evident in the 
grossly abnormal regions of AP embryos, analysis of early 
mesodermal markers by Northern blotting (Figure 3H) re- 
vealed that mesoderm formation is deficient. Overall, the 
AP phenotype is quite similar to that produced by domi- 
nant negative FGFR (Amaya et al., 1991, 1993) or domi- 
nant negative Raf (MacNicol et al., 1993), a downstream 
component of the FGF pathway. 
Our data suggest a positive role for SH-PTP2 in FGF 
signaling. This notion is supported by the ability of AP to 
block the immediate ffects of FGF (e.g., MAPK activation) 
in animal cap assays (Figure 7; see below). However, it 
is possible that SH-PTP2 is required for positive signaling 
from multiple RPTKs, which, combined with interference 
with the FGF pathway, leads to the observed tail truncation 
phenotype. We suspect that XSH-PTP2 does function in 
several growth factor signaling pathways, since recent 
work (L. Perkins, personal communication) indicates that 
csw is required for signaling in the Drosophila EGFR (tor- 
pedo), FGFR (breathless), and sevenless pathways. HSH- 
PTP2 (but not HSH-PTP1) efficiently complements csw in 
these pathways, strongly suggesting functional homology 
and implying that SH-PTP2 participates in multiple signal- 
ing pathways. Consistent with this hypothesis, SH-PTP2 
physically interacts with multiple RPTKs in mammalian 
cells (see Introduction). Moreover, after submission of this 
manuscript, several groups reported that SH-PTP2 is re- 
quired for positive signaling from the insulin receptor (Xiao 
et al., 1994; Milarski and Saltiel, 1994; Noguchi et al., 
1994). Although all available data in Drosophila, Xenopus, 
and mammals suggest that SH-PTP2 and its homologs 
are positive signaling elements, we cannot exclude a sub- 
sequent role for SH-PTP2 in termination of RPTK signals. 
Such a role could be obscured by blocking its positive 
signaling function. 
Both activin- and bFGF-induced expression of Xbra and 
muscle-specific actin (Figures 6A and 6B) were blocked 
in animal caps from AP-injected embryos. SH-PTP2 could 
be directly involved in both FGF and activin signaling. 
However, high level expression of a dominant negative 
FGFR blocks activin signaling, indicating that FGF may 
mediate part of the activin signal (LaBonne and Whitman, 
1994; Cornell and Kimelman, 1994). The apparent require- 
ment for SH-PTP2 in activin signaling may be secondary 
to the role of SH-PTP2 in the FGF pathway. 
Our data has several important implications for under- 
standing SH-PTP2 signal transduction. Presumably, AP 
competes with XSH-PTP2for binding to an Upstream 
phosphotyrosyl protein(s). An obvious potential target is 
the XFGFR, since it contains a tyrosine matching the con- 
sensus binding site for the N-terminal SH2 domain of SH- 
PTP2 (Musci et al., 1990). Although we see a substantial 
(5- to 10-fold) increase in tyrosine phosphorylation of SH- 
PTP2 when it is coinjected with wild-type FGFR (data not 
shown), suggesting SH-PTP2/FGFR interaction, we have 
been unable to demonstrate a direct physical association. 
This may be due to the limitations of our immunological 
reagents. However, it is also possible that the FGFR and 
SH-PTP2 do not stably associate; further experiments are 
required to resolve this issue. 
Because an intact PTP domain is required for rescue 
of AP, we infer that PTP activity is required for positive 
signaling. Injection of a C~S mutant of HSH-PTP2 in its 
essential catalytic ysteine produces the same phenotype 
as AP (unpublished data), further supporting a positive 
role for PTP activity. Different domains of SH-PTP2 may 
be required for positive signaling in different pathways. 
Recent data in mammalian cells implicates the C-terminus 
of SH-PTP2 in PDGFR signaling (Li et al., 1994; Bennett 
et al., 1994). Tyrosine phosphorylation within the SH-PTP2 
C-terminus creates one or more binding sites for GRB2, 
suggesting that tyrosine-phosphorylated SH-PTP2 func- 
tions as an adapter to couple the PDGFR to Ras activation. 
However, there is no direct proof of the functional signifi- 
cance of these phosphorylation sites and/or of SH-PTP2/ 
GRB2 association. In addition, no data excludes a role for 
the PTP domain in the PDGFR pathway. The SH-PTP2 
C-terminal Y-+F mutants did not affect early Xenopus em- 
bryo development and these mutants can rescue AP, indi- 
cating that tyrosine phosphorylation is not absolutely re- 
quired for SH-PTP2 function. Tyrosine phosphorylation 
may be critical only in some pathways or may play a modu- 
latory role that our assays cannot detect. 
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Finally, our results shed light on the likely position of 
SH-PTP2 in RPTK signaling pathways. The PTP domain 
requirement implies there must be an SH-PTP2 target(s) 
that becomes activated upon dephosphorylation. Attrac- 
tive candidates are src family PTKs, which are negatively 
regulated by C-terminal tyrosine phosphorylation (Kmiecik 
and Shalloway, 1987; Cartwright et al., 1987; Piwnica- 
Worms et al., 1987) and which associate with some RPTKs 
(Kypta et al., 1990). Alternatively, a novel tyrosine phos- 
phoprotein(s) may be the target. The ability of Ap  to block 
FGF-induced MAPK activation (Figure 7) positions SH- 
PTP2 downstream of the FGFR and upstream of MAPK. 
Our data on XSH-PTP2 are consistent with experiments 
on csw. Activated p21v'ras rescues the maternal-effect phe- 
notypes of both torso and csw null mutations. This effect 
is dependent on Drosophila Raf activity (Lu et al., 1993), 
placing csw downstream of torso, but upstream of Ras 
and Raf. Accordingly, microinjection of dominant negative 
Ras into Drosophila embryos produces a csw-like pheno- 
type (Lu et al., 1993). In mammal ian cells, expression of 
catalytically inactive SH-PTP2 was reported to block insu- 
lin-induced MAPK induction (Milarski and Saltiel, 1994; 
Noguchi et al., 1994) and GTP loading of c-Ras (Noguchi 
et al., 1994). All of these data suggest that SH-PTP2 lies 
upstream of Ras, at least in some signaling pathways. The 
relative position of SH-PTP2 and Ras in early Xenopus 
development may be more complex. In Xenopus embryos, 
microinjection of high concentrations of p21v-~" produces 
cell cycle arrest (Daar et al., 1991) and MAPK activation 
(unpublished data). Injection of lower amounts of p21 .... 
results in mesoderm induction (Whitman and Melton, 
1989). Coinjection of AP fails to block either Ras-induced 
cell cycle arrest or MAPK activation (unpublished data). 
Likewise, AP does not extinguish mesoderm induction 
produced by p21v-r% although preliminary experiments 
suggest that there may be a decrease in the total mass 
of mesoderm in coinjected embryos. A possible explana- 
tion for this complexity is provided by recent evidence for 
an FGF autocrine loop in early Xenopus embryos (Isaacs 
et al., 1994). Such a loop could make SH-PTP2 appear 
to be both upstream and downstream of p21 v-r~. Further 
experiments are required to elucidate the direct targets 
of SH-PTP2 action and to clarify how these targets lead 
to MAPK activation. 
Experimental Procedures 
Full-Length Constructs 
XSH-PTP2 was isolated by low stringency hybridization of random- 
primed full-length HSH-PTP2 to 1 x 106 plaques of a XZAPII stage 
17 cDNA library (Thomsen et al., 1990). Hybridizations were performed 
in 20% formamide, 6x SSC, and 1% SDS. Washes were carried out 
in 2 x SSC, 0.1% SDS twice for 30 min at room temperature, followed 
by 0.2x SSC, 0.1% SDS twice for 30 rain at 42°C. Plasmids were 
recovered from purified plaques by superinfection with single-strand 
helper phage, as per the instructions of the manufacturer (Stratagene). 
One partial clone was used to screen a Zgtl0 Xenopus oocyte cDNA 
library (Rebagliati et al., 1965). Inserts from isolated plaques were 
subcloned into pBlueScript (Stratagene) by polymerase chain reaction 
(PCR) using Vent polymerase (New England Biolabs) or by restricting 
isolated phage DNA with EcoRI. Subcloned inserts were sequenced 
on both strands on a 373A DNA sequencer (Applied Biosystems, Inc.). 
DNA and amino acid sequences were analyzed using BLAST (Altschul 
et al., 1990) or the Genetics Computer Group programs (Devereux et 
al., 1984). 
Mutant Construction 
A 93 nucleotide in-frame deletion in the HSH-PTP2 PTP domain was 
made by PCR-generated overlap extension (Innis et al., 1990). Using 
the primers 5'-GCACCATAAGCTTGAGAGCATC-3' and 5'-GATGCTC- 
TCAAGCTTATGGTGC-3', a Hindlll restriction site was introduced by 
each primer during amplification of the N-terminal and C-terminal frag- 
ments: PCRcgenerated products were digested with Hindlll and EcoRI, 
then cloned via three-way ligation into pSP64RI (see below) linearized 
with EcoRl. The resultant protein lacks 31 amino acids (amino acids 
446-476) including the essential catalytic VHCSAG motif (Guan and 
Dixon, 1991). Single and double Y~F mutants of HSH-PTP2 C-terminal 
tyrosines have been described (Bennett et al., 1994). 
Plasmid Constructs and In Vitro Transcriptions 
For in vitro transcription, SH-PTP2 constructs were inserted into the 
modified pSP64T (Krieg and Melton, 1984) vector pSP64RI (S. Sokol, 
unpublished data), which contains a polylinker flanked by Xenopus 
[~-globin 5' and 3' untranslated sequences. Xenopus FGFR constructs 
(Amaya et al., 1991) were from E. Amaya. In vitro transcription of 
linearized plasmids was carried out using SP6 polymerase and the 
MEGAscript kit (Ambion). 
Embryo Manipulations 
Fertilization and embryo culture in 0.1 x MMR were performed as 
described (Newport and Kirschner, 1982a). Embryos were transferred 
to 0.5x MMR, 3% Ficoll (Sigma) and injected with 10 nl of 0.5-1 rag/ 
ml RNA. For animal cap assays, embryos were injected in the animal 
pole at the 1-2 cell stage. To assay whole embryos, injections in the 
dorsal marginal zone were performed on pigmented embryos that 
showed a clear dorsal-ventral axis at the 4-cell stage. Embryos were 
transferred to 0.1 x MMR and allowed to develop at room temperature 
for 4-5 hr. Staging was according to Nieuwkoop and Faber (1967). 
Embryonic explants were fixed in 0.75 x PBS plus 3.7% formaldehyde 
for I hr at room temperature, and histological analysis was performed 
as described (Sokol et al., 1990). 
Animal caps were excised from midblastulae (stage 8-8.5) and cul- 
tured in low calcium medium (Itoh and Sokol, 1994) with or without 
growth factors until stage 11. Explants were cultured further in 0.7 x 
MMR or lysed for early marker analysis. Recombinant human bFGF 
(GIBCO) was used at 60-100 ng/ml and recombinant human activin 
A (Itoh and Sokol, 1994) at 5 ng/ml. 
RNA and Protein Analysis 
RNA extraction and Northern analysis of early and late markers was 
performed as described (Itoh and Sokol, 1994). Animal caps dissoci- 
ated in calcium-free, magnesium-free normal amphibian media(Green 
and Smith, 1990) were either left untreated or treated with 100 ng/ml 
bFGF for 5 rain, pelleted, and frozen. These were lysed in oocyte lysis 
buffer (250 mM sucrose, 100 mM NaCI, 2.5 mM MgCI2, 10 mM NaF, 
10 mM EGTA, 1 mM Na3VO4, 20 mM HEPES [pH 7.2], and 10/0 Triton 
X-100) containing protease inhibitors (10 i~g/ml eupeptin, 1 i~g/ml 
aprotinin, 1 I~g/ml pepstatin A, 1 i~g/ml antipain, and 20 I~g/ml phenyl- 
methylsulfonyl f uoride), clarified at 13,000 rpm for 5 min at 4°C, elec- 
trophoresed, and blotted onto Immobilon P (Millipore). Total protein 
was prepared from manually defolliculated stage VI oocytes by similar 
procedures. 
Sf9 cells were infected with HSH-PTP2 baculovirus, incubated for 
two days at 27°C, and lysed in NP-40 buffer (Lechleider et al., 1993b). 
Construction and characterization of the virus will be described else- 
where. Soluble lysates were quantitated by BCA assay (Pierce), re- 
solved by SDS-PAGE, and transferred onto Immobilon P. Immu- 
noblots were probed with C-terminal anti-Xenopus MAPK rabbit 
polyclonal antibodies (Hartley et al., 1994), rabbit antibodies against 
HSH-PTP1 (Lorenz et al., 1994), or mouse monoclonal anti-PTP1D/ 
SH-PTP2 antibody (Transduction Laboratories), incubated with either 
anti-mouse- or anti-rabbit-horseradish peroxidase secondary anti- 
bodies and developed by enhanced chemiluminescence (ECL; 
Amersham). 
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